Guided Therapeutics, Inc.
GTHP
$0.25
$0.0525.00%
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -5.91% | -63.86% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 99.08% | -- | |||
| Total Operating Expenses | 58.28% | -80.77% | |||
| Operating Income | -58.28% | 69.20% | |||
| Income Before Tax | -21.00% | 58.95% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -21.00% | 58.95% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -21.00% | 58.95% | |||
| EBIT | -58.28% | 69.20% | |||
| EBITDA | -58.67% | 69.31% | |||
| EPS Basic | 44.74% | 22.45% | |||
| Normalized Basic EPS | -11.43% | 61.54% | |||
| EPS Diluted | 12.28% | 22.45% | |||
| Normalized Diluted EPS | -11.43% | 61.54% | |||
| Average Basic Shares Outstanding | 8.67% | 5.01% | |||
| Average Diluted Shares Outstanding | 8.67% | 5.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||